All data are based on the daily closing price as of December 23, 2024
e

Eisai

4523.TSE
27.29 USD
-0.26
-0.94%

Overview

Last close
27.29 usd
Market cap
7.69B usd
52 week high
64.37 usd
52 week low
27.29 usd
Target price
41.07 usd

Valuation

P/E
30.1207
Forward P/E
32.6797
Price/Sales
1.5988
Price/Book Value
1.4836
Enterprise Value
7.22B usd
EV/Revenue
1.5007
EV/EBITDA
11.2465

Key financials

Revenue TTM
4.81B usd
Gross Profit TTM
3.62B usd
EBITDA TTM
514.78M usd
Earnings per Share
0.92 usd
Dividend
1.02 usd
Total assets
8.83B usd
Net debt
-756.27M usd

About

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
  • Symbol
    4523.TSE
  • Exchange
    TSE
  • Isin
    JP3160400002
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Haruo Naito
  • Headquarter
    Tokyo
  • Web site
    https://www.eisai.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top